Skip Navigation

Annals of Oncology 2006 17(9):1339; doi:10.1093/annonc/mdl326
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Improving capecitabine/docetaxel tolerability
 
Because the combination of capecitabine and docetaxel improves survival compared with docetaxel monotherapy in anthracycline-pretreated patients with metastatic breast cancer, it represents a standard of care for anthracycline-pretreated patients. However, in a phase III trial the capecitabine/docetaxel combination therapy was associated with toxicities that were consistent with the known side effects of the individual agents. There was a higher incidence of gastrointestinal adverse events and hand-foot syndrome in the combination . . . [Full Text of this Article]


   Temozolomide/cisplatin for patients with NSCLC and brain metastases
 

   Maintnence rituximab for mantle cell lymphoma
 

   Body size and laryngeal cancer
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?